Theralase net loss narrows 14% to CAD 2.09 million in FY26 H1; revenue slips 5% to CAD 296,927 in FY26 H1

• Theralase posted a net loss of CAD 2.09 million for the six months ended June 30, 2026, narrowing 14% year over year.
• Revenue slipped 5% to CAD 296,927.
• Gross margin widened to 50% from 42% a year earlier.
• Net R&D expenses fell 25% to CAD 1.1 million, on lower Study II patient enrollment and treatment costs.
• Cash climbed to CAD 5.26 million at June 30, 2026; it later raised CAD 3.56 million in an Aug. 24 private placement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608281636NEWSFILECNPR____20260828_311984_1) on August 28, 2026, and is solely responsible for the information contained therein.